High Immune Infiltration Predicts Worse Outcomes in Bevacizumab-Treated Ovarian Cancer Patients
核心洞察
High CD8 (搜索)+ T cell infiltration in ovarian cancer (搜索) tumors is associated with shorter progression-free survival in patients receiving first-line bevacizumab treatment, contrary to expectations from chemotherapy-only studies.
The immunoreactive molecular subtype, typically associated with better prognosis, showed worse outcomes with median PFS of 25 months compared to 37 months for the mesenchymal subtype in bevacizumab-treated patients.
Multiplex immunofluorescence analysis of 292 patient samples revealed that high total CD8 (搜索)+ infiltration nearly doubled the risk of disease progression (HR 1.94) in the phase 4 MITO16A trial.
A comprehensive analysis of tumor-infiltrating immune cells in epithelial ovarian cancer (搜索) patients has revealed an unexpected finding: high levels of immune infiltration, particularly CD8 (搜索)+ T cells, are associated with worse outcomes in patients receiving bevacizumab treatment. This counterintuitive result challenges conventional understanding and suggests that immune profiling could help identify patients less likely to benefit from the anti-angiogenic therapy.
The findings come from the phase 4 MITO16A-MaNGO OV-2 clinical trial, which enrolled 398 patients with advanced epithelial ovarian cancer (搜索) receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab. The study represents the first large multicenter trial in ovarian cancer (搜索) to employ spatial multiplex immunofluorescence (MIF) analysis across nearly 90% of enrolled patients.
Molecular Subtypes Show Reversed Prognostic Patterns
Gene expression profiling analysis of 197 patient samples classified tumors into four established molecular subtypes: immunoreactive (IMM), differentiated (DIFF), proliferative (PRO), and mesenchymal (MES). The results revealed a striking reversal of expected prognostic patterns when bevacizumab was added to standard chemotherapy.
The immunoreactive subtype, typically associated with the best prognosis in ovarian cancer (搜索), showed unexpectedly poor outcomes with a median progression-free survival (PFS) of 25 months using both TCGA and Tothill classifiers. In contrast, the mesenchymal subtype, usually linked to worse prognosis, demonstrated better outcomes with a median PFS of 37 months using the TCGA classifier and 29 months using the Tothill classifier.
"These data suggested that the addition of [bevacizumab] to standard chemotherapeutic treatment differently affects the prognosis of these 2 molecular subtypes, with a detrimental effect for the specific subgroup of patients characterized by a more pronounced immune-related transcriptomic profile," the researchers noted.
Spatial Analysis Confirms Immune Infiltration Impact
The study employed multiplex immunofluorescence analysis on 292 patient samples to precisely quantify and spatially localize immune cells. This advanced technique distinguished between cells infiltrating the tumor itself (intratumor) and those in the surrounding stromal tissue, providing unprecedented detail about the tumor microenvironment.
The analysis revealed that high CD8 (搜索)+ T cell infiltration was significantly associated with shorter PFS. When patients were stratified using optimal cutoff values, high total CD8+ infiltration was associated with a hazard ratio of 1.94 (95% CI: 1.15-3.27; p = 0.012), representing nearly a twofold increased risk of disease progression. This association remained statistically significant after adjustment for over-fitting using bootstrap-percentile methods.
Tumor-specific CD8 (搜索)+ infiltration showed a hazard ratio of 1.83 (95% CI: 1.07-3.12; p = 0.025), while stromal CD8+ infiltration demonstrated a hazard ratio of 1.89 (95% CI: 1.11-3.22; p = 0.018). Notably, CD68 (搜索)+ macrophage infiltration did not show significant associations with either PFS or overall survival.
Immunologically "Cold" Tumors Identified
The comprehensive immune profiling revealed substantial heterogeneity in the ovarian cancer (搜索) tumor microenvironment. A notable proportion of tumors were classified as immunologically "cold," with 30% of samples completely negative for CD8 (搜索)+ cells and 6% negative for CD68 (搜索)+ cells. This finding aligns with the historically limited success of immunotherapy approaches in ovarian cancer.
The moderate to high correlation observed between CD8 (搜索)+ and CD68 (搜索)+ cells infiltrating the tumor and surrounding stroma of the same sample suggests coordinated immune responses within individual tumors, though correlation between different samples was low to non-significant.
Clinical Implications for Treatment Selection
The combined analysis of MIF and gene expression data on 171 patients showed that individuals with the worst prognosis typically had high levels of both CD8 (搜索)+ and CD68 (搜索)+ infiltration and belonged predominantly to the proliferative molecular subtype. This finding provides a potential framework for identifying patients who may not benefit from bevacizumab maintenance therapy.
The researchers propose that evaluating immune infiltration at diagnosis, particularly CD8 (搜索)+ T cell density, could contribute to better personalization of ovarian cancer (搜索) therapy. However, they emphasize that these findings require validation in randomized clinical trials directly comparing treatments with and without anti-angiogenic agents.
Study Limitations and Future Directions
The analysis was limited to samples collected at diagnosis, leaving unclear whether bevacizumab treatment leads to changes in immune infiltration over time. Additionally, 18% of processed samples could not be analyzed by MIF due to technical failures during staining procedures, with failures more frequent in peritoneal metastatic samples compared to primary ovarian tumors.
The study also lacked a chemotherapy-only comparator arm, preventing definitive conclusions about the predictive versus prognostic value of immune infiltration in bevacizumab-containing regimens. The researchers acknowledge that the observed associations may represent cohort-specific effects requiring broader validation.
Despite these limitations, the findings provide compelling evidence that immune infiltration assessment could inform treatment decisions in ovarian cancer (搜索). The researchers suggest that future studies should investigate the biological mechanisms linking VEGF (搜索) blockade with altered immune response patterns and explore whether immune profiling can guide therapeutic selection in prospective clinical trials.